PROMETHEUS BIOSCIENCES INC (RXDX) Stock News
NASDAQ:RXDX - Nasdaq - US74349U1088 - Common Stock - Currency: USD
RXDX Latest News, Press Relases and Analysis
Merck Raises 2023 Sales Forecast as Cancer Drug Keytruda, Gardasil Vaccine Surge
Merck & Co.’s Keytruda and Gardasil soundly beat analysts’ estimates for quarterly sales, driving the company’s annual revenue forecast higher even as costs for its acquisition of Prometheus Biosciences Inc. led to a cut in its annual earnings outlook.
Why Shares of Exscientia Jumped on Wednesday
The company may be riding the wave of an AI healthcare boom.
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.
Why Shares of Ventyx Biosciences Rose Monday
The company has several promising autoimmune therapies.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, RADI, FOCS
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
3 Innovative Growth Stocks to Buy for Next-Gen Profits
These are the innovative growth stocks for future profits as they represent companies investing significantly in research and development.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, MDWT, RUTH
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
3 Undervalued Pharma Stocks to Buy for High Total Returns
These are the undervalued pharma stocks to buy as they represent companies investing heavily in research to boost the product pipeline.
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S.
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTV, RXDX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: MNTV
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
- Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 -...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report
Abbvie (ABBV) and Bristol-Myers Squibb (BMY) competed to takeover Prometheus Biosciences (RXDX), before Merck (MRK) won in its pursuit of the biotech company. The interest from...
AbbVie, Bristol Myers Vied for Prometheus Before Merck Bought It
Merck & Co. edged out competitors including AbbVie Inc. and Bristol Myers Squibb Co. to prevail in its $10.8 billion takeover of biotechnology company Prometheus Biosciences Inc, according to people familiar with the matter.
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
The major indexes saw modest declines, holding in a range.
Beaten-Down Biotech Stocks Get Boost from M&A Boom, Lofty Prices
The resurgence of deal activity in the drug-development industry is driving investors’ interest in biotech stocks and boosting values for potential takeover targets.